| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a98cb1b197f761c87cd3caf32bc247e2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-00 |
| filingDate |
2008-04-04^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f42cfb4d9a60f6ff07ce2f5626f313ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2a96685e6efbc2b810c5fd66e579ec9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8d035e47a3a2981efcce17e86d3c4ff |
| publicationDate |
2010-05-13^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010120709-A1 |
| titleOfInvention |
Cytidine derivative-containing antitumor agent for continuous intravenous administration |
| abstract |
To provide a method for administering ECyd to a patient, which realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and which exhibits an excellent therapeutic effect with ensuring prolongation of the survival of the patient. n The invention provides an antitumor agent containing ECyd or a salt thereof, which is administered to a cancer patient through continuous intravenous administration at a dose of 1.30 to 8.56 mg/m 2 as reduced to ECyd, for each administration period of 2 to 336 hours. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011118205-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8586561-B2 |
| priorityDate |
2007-04-06^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |